Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN

Morgan, Eileen; Arnold, Melina; Gini, Andrea; Lorenzoni, Valentina; Cabasag, Citadel J.; Laversanne, Mathieu; Vignat, Jérôme; Ferlay, Jacques; Murphy, Neil; Bray, Freddie

doi:10.1136/gutjnl-2022-327736

Cited by 601 publications

(396 citation statements)

References 42 publications

Supporting

Mentioning

262

Contrasting

Unclassified

Order By: Relevance

“…Colorectal cancer (CRC) is a leading cause of cancer-related mortality and morbidity worldwide and represents a significant public health challenge in Romania [ 1 ]. According to the GLOBOCAN database, CRC is the most frequent type of cancer in Romania [ 2 , 3 ]. The diagnosis of CRC is often delayed due to the limited availability of screening programs and low public awareness about the importance of early detection.…”

Section: Introductionmentioning

confidence: 99%

Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice

et al. 2023

View full text Add to dashboard Cite

Background and Objectives: Colorectal cancer (CRC) is a leading cause of cancer-related mortality and morbidity worldwide. Bevacizumab was approved for the treatment of metastatic colorectal cancer (mCRC) based on favorable benefit-risk assessments from randomized controlled trials, but evidence on its use in the real-world setting is limited. The aim of the current study is to evaluate the outcomes and safety profile of bevacizumab in mCRC in a real-world setting in Romania. Patients and Methods: This was an observational, retrospective, multicentric, cohort study conducted in Romania that included patients with mCRC treated with bevacizumab as part of routine clinical practice. Study endpoints were progression-free survival, overall survival, adverse events, and patterns of bevacizumab use. Results: A total of 554 patients were included in the study between January 2008 and December 2018. A total of 392 patients (71%) received bevacizumab in the first line and 162 patients (29%) in the second line. Bevacizumab was mostly combined with a capecitabine/oxaliplatin chemotherapy regimen (31.6%). The median PFS for patients treated with bevacizumab was 8.4 months (interquartile range [IQR], 4.7–15.1 months) in the first line and 6.6 months (IQR, 3.8–12.3 months) in the second line. The median OS was 17.7 months (IQR, 9.3–30.6 months) in the first line and 13.5 months (IQR, 6.7–25.2 months) in the second line. Primary tumor resection was associated with a longer PFS and OS. The safety profile of bevacizumab combined with chemotherapy was similar to other observational studies in mCRC. Conclusions: The safety profile of bevacizumab was generally as expected. Although the PFS was generally similar to that reported in other studies, the OS was shorter, probably due to the less frequent use of bevacizumab after disease progression and the baseline patient characteristics. Patients with mCRC treated with bevacizumab who underwent resection of the primary tumor had a higher OS compared to patients with an unresected primary tumor.

show abstract

Section: Introductionmentioning

confidence: 99%

Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice

et al. 2023

View full text Add to dashboard Cite

show abstract

“…CRC is the third most common cancer in men and the second in women world-wide [1, 2]. Symptoms are often unspecific, and many cases are detected at an advanced stage with reduced prospects for curative treatment.…”

Section: Introductionmentioning

confidence: 99%

Long term follow-up of colorectal cancer screening attendees identifies differences inPhascolarctobacterium spp. using 16S rRNA and metagenome sequencing

Bucher-Johannessen

Birkeland

Vinberg

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: The microbiome has been implicated in the initiation and progression of colorectal cancer (CRC) in cross sectional studies. However, there is a lack of studies using prospectively collected samples. Methods: We analysed 144 archived faecal samples from participants in the NORwegian Colorectal CAncer Prevention (NORCCAP) trial diagnosed with CRC or high-risk adenomas (HRA) at screening, or who remained cancer-free during 17 years of follow-up. We performed 16S rRNA sequencing of all samples, and metagenome sequencing on a subset of 47 samples. Differences in taxonomy and gene content between outcome groups were assessed for alpha and beta diversity, and differential abundance. Results: Diversity and composition analyses showed no significant differences between CRC, HRA, and healthy controls. Phascolarctobacterium succinatutens was more abundant in CRC compared to healthy controls in both the 16S and metagenome data. The abundance of Bifidobacterium and Lachnospiraceae spp. were associated with time to CRC diagnosis. Conclusion: Using a longitudinal study design, we identified three taxa as being potentially associated with CRC. These should be the focus of further studies of microbial changes occurring prior to CRC diagnosis.

show abstract

“…As the third most common and second most deadly malignancy globally, colorectal cancer (CRC) caused over 1.9 million new cases and 0.9 million deaths in 2020 [ 1 ]. The burden is projected to increase to 3.2 million new cases and 1.6 million deaths by 2040 [ 2 ]. Obesity, a major public health concern worldwide, has been recognized as a leading risk factor for CRC [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

A Metabolomic Signature of Obesity and Risk of Colorectal Cancer: Two Nested Case–Control Studies

Yang

Zhu

et al. 2023

Metabolites

View full text Add to dashboard Cite

Obesity is a leading contributor to colorectal cancer (CRC) risk, but the metabolic mechanisms linking obesity to CRC are not fully understood. We leveraged untargeted metabolomics data from two 1:1 matched, nested case–control studies for CRC, including 223 pairs from the US Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial and 190 pairs from a prospective Chinese cohort. We explored serum metabolites related to body mass index (BMI), constructed a metabolomic signature of obesity, and examined the association between the signature and CRC risk. In total, 72 of 278 named metabolites were correlated with BMI after multiple testing corrections (p FDR < 0.05). The metabolomic signature was calculated by including 39 metabolites that were independently associated with BMI. There was a linear positive association between the signature and CRC risk in both cohorts (p for linear < 0.05). Per 1-SD increment of the signature was associated with 38% (95% CI: 9–75%) and 28% (95% CI: 2–62%) higher risks of CRC in the US and Chinese cohorts, respectively. In conclusion, we identified a metabolomic signature for obesity and demonstrated the association between the signature and CRC risk. The findings offer new insights into the underlying mechanisms of CRC, which is critical for improved CRC prevention.

show abstract

Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN

Cited by 601 publications

References 42 publications

Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice

Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice

Long term follow-up of colorectal cancer screening attendees identifies differences inPhascolarctobacterium spp. using 16S rRNA and metagenome sequencing

A Metabolomic Signature of Obesity and Risk of Colorectal Cancer: Two Nested Case–Control Studies

Contact Info

Product

Resources

About